NR1H4 and metabolic dysfunction-associated steatotic liver disease: Supplementation of high-fat or db/db mice with either TGR5 or FXR agonists inhibits lipogenesis, induces energy expenditure and reduces hepatic and renal inflammation to reduce the development of NAFLD and DKD 124.